Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cerus Corporation is a biomedical products company focused on developing and commercializing pathogen reduction technologies designed to enhance the safety of the global blood supply. The company operates within the biotechnology and medical devices industries, with a specific emphasis on transfusion medicine and blood safety. Cerus’s core offering is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens in blood components.
The company primarily generates revenue through the sale of disposable kits, illuminators, and related services associated with the INTERCEPT Blood System for platelets and plasma, with development activities ongoing for red blood cells. Cerus serves blood centers, hospitals, and national blood services, with a strong strategic position driven by regulatory approvals, long-term supply agreements, and increasing regulatory focus on blood safety. Founded in 1991, Cerus evolved from a research-oriented biotechnology firm into a commercial-stage company following regulatory approvals in Europe and later the United States, significantly expanding its market reach over the past decade.
Business Operations
Cerus operates as a single-reportable-segment company, generating revenue primarily from the commercialization of the INTERCEPT Blood System, which includes single-use processing kits, ultraviolet illumination devices, and ongoing service and support. The company’s business model is largely consumables-driven, providing recurring revenue tied to blood component processing volumes. While Cerus conducts research and development internally, manufacturing is supported through a combination of internal capabilities and third-party contract manufacturers.
Operations span both domestic and international markets, with commercial activity concentrated in North America and Europe, and growing adoption in select regions of Asia-Pacific, Latin America, and the Middle East. Cerus maintains strategic distribution and commercialization partnerships with regional blood service organizations and medical technology distributors, while retaining direct sales capabilities in key markets. The company does not currently report material joint ventures but works closely with national health authorities and blood operators to support implementation and regulatory compliance.
Strategic Position & Investments
Cerus’s strategic direction centers on expanding global adoption of pathogen reduction as a standard of care in transfusion medicine. Key growth initiatives include deeper penetration of the U.S. platelet and plasma markets, expansion into additional international jurisdictions, and continued development of the INTERCEPT Red Blood Cell System, which represents a significant long-term growth opportunity. The company has invested heavily in clinical development, regulatory submissions, and post-market studies to support broader labeling and reimbursement.
Rather than pursuing frequent acquisitions, Cerus has historically focused on internal innovation and targeted investments aligned with its core technology platform. The company’s intellectual property portfolio and regulatory approvals serve as important strategic assets, creating barriers to entry in the pathogen reduction space. Emerging areas of focus include preparedness for emerging infectious diseases and strengthening supply chain resilience for blood safety technologies.
Geographic Footprint
Cerus is headquartered in Concord, California, and operates primarily across North America and Europe, which together represent the majority of its revenue. The INTERCEPT Blood System is approved and marketed in dozens of countries, with especially strong adoption in Western Europe, where pathogen reduction is widely integrated into national blood safety policies.
Beyond its core markets, Cerus maintains an expanding presence in Asia-Pacific, Latin America, and parts of the Middle East, typically through distributors or partnerships with national blood services. While international markets currently contribute a smaller share of revenue compared to the United States and Europe, they represent a key component of the company’s long-term growth strategy due to increasing regulatory focus on transfusion safety.
Leadership & Governance
Cerus is led by an executive team with experience spanning biotechnology, medical devices, and global healthcare commercialization. The leadership emphasizes a mission-driven approach centered on improving public health through safer blood transfusions, with strategic priorities focused on regulatory execution, disciplined growth, and long-term technology development.
Key executives include:
- Obi Greenman – President and Chief Executive Officer
- Kevin D. Green – Chief Financial Officer
- Vivek Jayaraman – Chief Operating Officer
- Richard J. Benjamin – Chief Medical Officer
- Claudio Rado – Senior Vice President, Global Operations
The board of directors provides governance oversight with a focus on regulatory compliance, capital allocation, and long-term shareholder value, reflecting the company’s status as a publicly traded life sciences organization.